Amir T Fathi, MD

Trials

Studies that name Amir T Fathi, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:02 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06707493 · Ivosidenib as Post-HSCT Maintenance for AML

  Massachusetts General Hospital · recruiting · IDH1 Mutation, Acute Myeloid Leukemia (AML), Hematopoietic Stem Cell Transplant (HSCT) · principal investigator
• Ph2
  NCT04801797 · Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

  Massachusetts General Hospital · active not recruiting · Acute Myeloid Leukemia · principal investigator
• Ph1
  NCT03564821 · IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

  Massachusetts General Hospital · completed · IDH1 Mutation Myeloid Neoplasms · principal investigator
• Ph1
  NCT03515512 · IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

  Massachusetts General Hospital · completed · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia · principal investigator
• Ph1
  NCT02905994 · Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

  Massachusetts General Hospital · withdrawn · AML · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.